Option chain shows key data for Vaccinex's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Vaccinex.

Vaccinex (OTC:VCNX) Stock, Option Chain

Vaccinex

Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.

10 New Updates On COVID And Vaccines From CDC That You Need To Know

News

Movers

VCNX

Vaccinex, Inc. (NASDAQ: VCNX) shares are trading lower after the company announced it received a delisting notification from Nasdaq. Here&#39;s what you need to know.

Vaccinex Faces Nasdaq Delisting: What&#39;s Going On With The Stock?

Energy stocks

Earnings

Equities

Eurozone

Commodities

Markets

Trading Ideas

DBGI

PRTG

QUBT

TNXP

TNYA

Crude Oil Down Over 1%; US Industrial Production Declines In November

retail-sales-ai

Intraday Update

OPTX

Dow Dips Over 200 Points; US Retail Sales Top Estimates

Vaccinex Inc

As of Jan. 23, 2025, three stocks in the information technology sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Kopin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOPN#NASDAQ">KOPN</a>)</h3>
<ul>
<li>Kopin shares rose sharply on Wednesday amid a report suggesting the company may be interested in competing for an Army contract. The company's stock surged around 20% over the past five days and has a <a href="https://www.benzinga.com/quote/KOPN">52-week high of $2.82</a>.</li>
<li>RSI Value: 77.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>KOPN Price Action: Shares of Kopin gained 14% to close at $1.47 on Wednesday.</li>
</ul>
<h3 class="wp-block-heading">Guidewire Software Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>)</h3>
<ul>
<li>Guidewire Software will replace Arrowhead Pharmaceuticals in the S&amp;P MidCap 400, effective prior to opening of trading on Jan. 27. The company's stock gained around 5% over the past five days and <a href="https://www.benzinga.com/quote/GWRE">has a 52-week high</a> of $209.14.</li>
<li>RSI Value: 72.5</li>
<li>GWRE Price Action: Shares of Guidewire Software gained 1.1% to close at $183.49 on Wednesday.</li>
</ul>
<h3 class="wp-block-heading">Himax Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIMX#NASDAQ">HIMX</a>)</h3>
<ul>
<li>On Jan. 10, Delta reported fourth-quarter adj. operating revenue growth of 5.7% year-over-year to $14.437 billion. GAAP operating revenue was $15.56 billion (+9.4% YoY), beating the consensus of $14.212 billion. The company's stock gained around 29% over the past five days and has a <a href="https://www.benzinga.com/quote/HIMX">52-week high</a> of $11.14.</li>
<li>RSI Value: 74.9</li>
<li>HIMX Price Action: Shares of Himax gained 3.8% to close at $9.92 on Wednesday.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43126364/jim-cramer-this-tech-stock-is-a-buy-amd-is-a-great-company">Jim Cramer: AMD Is A &#8216;Great&#8217; Company, Hold Onto Dow Inc.</a></li>
</ul>

Short Ideas

Pre-Market Outlook

GWRE

HIMX

KOPN

Top 3 Tech Stocks That Are Ticking Portfolio Bombs

Reinsurance Gr's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RGA#NYSE">RGA</a>) short percent of float has risen 46.03% since its last report. The company recently reported that it has 466 thousand shares sold short, which is 0.92% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.01 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Reinsurance Gr Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737638122_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Reinsurance Gr has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Reinsurance Gr's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Reinsurance Gr's peer group average for short interest as a percentage of float is 1.75%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Peering Into Reinsurance Gr's Recent Short Interest

On Thursday, Banzai International, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNZI#NASDAQ">BNZI</a>) announced that it has signed a definitive agreement to acquire Act-On Software Inc, an enterprise marketing automation platform (MAP) provider.
The aggregate merger consideration of $53.2 million will consist of common stock and pre-funded warrants exercisable for common stock, valued at $33.2 million, and a cash consideration of $20.0 million.
Act-On is an easy-to-use, intelligent marketing automation platform powered by AI and supported by an open data architecture.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/01/43130244/amphenol-q4-earnings-30-sales-growth-ceo-highlights-growth-in-it-mobile-and-defense-markets-forecasts-strong-q1-sales-growth" rel="noreferrer noopener">Amphenol Q4 Earnings: Revenue And EPS Beat, CEO Highlights Growth In IT, Mobile And Defense, Strong Q1 Forecast And More</a>
Clients like Hitachi, BestBuy, and Progressive Insurance utilize Act-On to improve lead generation, increase sales pipeline, automate customer communications, and increase return on marketing investment (ROMI).
Banzai founder and CEO Joe Davy noted that Act-On&#8217;s software complements Banzai&#8217;s suite of tools for data-driven marketers. By making customer data actionable, Act-On empowers marketers to create smart, effective programs to drive growth and increase customer lifetime value—all with exceptional speed and efficiency, Davy added.
The acquisition is projected to increase revenue by $27 million for the twelve-month period ending December 31, 2025, on a pro forma basis.
Banzai held $4.3 million in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41994365/banzai-reports-third-quarter-2024-financial-results-annualized-adjusted-net-loss-improvement-of-12" rel="noreferrer noopener">cash and equivalents</a> as of September 30, 2024
Price Action: At the last check on Thursday, BNZI stock traded higher by 1.21% to $1.67 in the premarket session.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/01/43102671/comcasts-wicked-hits-700-million-worldwide-breaks-records-as-top-grossing-stage-musical-adaptation" target="_blank" rel="noreferrer noopener">Comcast&#8217;s Wicked Hits $700 Million Worldwide, Breaks Records as Top-Grossing Stage Musical Adaptation</a></li>
</ul>

Market-Moving Exclusives

Exclusives

BNZI

EXCLUSIVE: Banzai To Snap Act-On Software For $53.2 Million, Expanding AI-Powered Marketing Tools for Clients Like BestBuy and Hitachi

Baker Hughes's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NYSE">BKR</a>) short percent of float has fallen 10.55% since its last report. The company recently reported that it has 13.65 million shares sold short, which is 1.78% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.4 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Baker Hughes Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737638117_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Baker Hughes has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Baker Hughes's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Baker Hughes's peer group average for short interest as a percentage of float is 8.43%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Baker Hughes?

On Thursday, La Rosa Holdings Corp (NASDAQ:&nbsp;LRHC) announced a preliminary revenue estimate of $65 million for fiscal year 2024, up 104% from the previous year.
CEO Joe La Rosa noted strategic acquisitions of real estate brokerage franchisees and a significant increase in agent count drove the performance.
Rosa expects that 2025 will be another strong year backed by its continued expansion plans.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/emerging-markets/25/01/43096797/huawei-wants-to-take-nvidias-place-in-ai-in-china-shifts-focus-to-inference-over-training" rel="noreferrer noopener">Huawei Wants To Take Nvidia&#8217;s Place In AI In China, Shifts Focus to Inference Over Training</a>
Rosa noted that the company is on track to close the previously announced acquisition of a real estate brokerage firm in the first quarter of 2025. The firm generated $19 million in revenue in 2023 and has a network of over 950 agents across multiple states.
Rosa plans to expand into new states, acquire additional real estate brokerage firms, increase agent count, and continuously enhance its technology.
Price Action: LRHC stock traded higher by 6.29% at $0.51 premarket at the last check on Thursday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/01/43095433/umc-q4-earnings-topline-rises-99-driven-by-ai-and-smartphones-projects-flat-q1-shipments" target="_blank" rel="noreferrer noopener">UMC Q4 Earnings: Topline Rises 9.9% Driven By AI And Smartphones, Projects Sequentially Flat Q1 Shipments</a></li>
</ul>

Guidance

LRHC

EXCLUSIVE: La Rosa Doubles Revenue to $65 Million in 2024, Plans Major Expansion and $19 Million Brokerage Acquisition

ZoomInfo Technologies's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZI#NYSE">ZI</a>) short percent of float has fallen 21.35% since its last report. The company recently reported that it has 25.21 million shares sold short, which is 8.07% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.47 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>ZoomInfo Technologies Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737638112_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for ZoomInfo Technologies has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing ZoomInfo Technologies's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, ZoomInfo Technologies's peer group average for short interest as a percentage of float is 6.79%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into ZoomInfo Technologies's Recent Short Interest

EXCLUSIVE: Banzai Tells Benzinga, Co Announces Acquisition Of Act-On Software For $53.2M To Enhance AI-Driven B2B Marketing Platform, Growing TTM Revenue 152% To $44M; Revenue Expected To Increase By $27M By The End Of 2025

EXCLUSIVE: La Rosa Holdings Tells Benzinga, Co. Reports Preliminary FY24 Revenue Of $65M, Up ~104% Year-Over-Year; Says "Anticipate That 2025 Will Be Another Strong Year As We Build On This Momentum With Ambitious Plans For Continued Expansion."

Solana's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) has surged 21% over the past week, driven by excitement over meme coin launches and anticipation of <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43064882/bitcoin-etfs-outperform-in-first-year-but-solana-xrp-etfs-face-challenges-expert-says">a futures ETF</a>.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$244.80</td>
<td>$119.1 billion</td>
<td>-4.6%&nbsp;</td>
<td>+21% </td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$3,208.51</td>
<td>$386.5 billion</td>
<td>-3.1%</td>
<td>-3.8%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$3.09</td>
<td>$177.7 billion</td>
<td>&nbsp;-2.6%&nbsp;</td>
<td> -2%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto trader Jelle predicts "more violent moves" ahead as Solana consolidates near its previous all-time highs.
He <a href="https://x.com/CryptoJelleNL/status/1882367467336712584">views</a> the current correction as a healthy pause after its recent rally, suggesting, "It's only a matter of time before the next leg higher."
Meanwhile, trader IncomeSharks warns that Solana memes may face another dip, citing the importance of reclaiming the $272 level for a sustained bullish move.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24SOL&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$SOL</a> &#8211; Still making lower highs. Solana memes probably have another lower flush coming. Reclaim $272 and this is invalided <a href="https://t.co/8CkorAwqqL">pic.twitter.com/8CkorAwqqL</a>
&mdash; IncomeSharks (@IncomeSharks) <a href="https://twitter.com/IncomeSharks/status/1882199521423429954?ref_src=twsrc%5Etfw">January 22, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Statistics: According to DeFiLlama, Solana's total value locked (TVL) has hit a record $11.6 billion as of today. 
On-chain revenue has also peaked at $5.9 million.
Santiment <a href="https://x.com/santimentfeed/status/1882156632110485836">data</a> reveals mixed sentiment on Solana, with a 3:2 ratio of negative vs. positive comments across platforms like X, Reddit and Telegram. 
The network's minor decoupling from other altcoins, supported by meme coin activity, has stirred retail uncertainty amid transaction delays.  
Data shows whales and sharks are accumulating SOL even as retail traders reduce their holdings.
Community News: Bloomberg's Senior ETF Analyst Eric Balchunas <a href="https://x.com/EricBalchunas/status/1882155132219216240">shared</a> that Volatility Shares is leading the race to launch a Solana Futures ETF, potentially by mid-March. 
However, Balchunas remains uncertain about sustained demand, especially with a spot ETF anticipated soon.
SolanaFloor <a href="https://x.com/SolanaFloor/status/1882156348328337897">announced </a>that CME Group will launch SOL Futures contracts on Feb. 10.
Coinbase CEO Brian Armstrong <a href="https://x.com/brian_armstrong/status/1881987902701207678">assured</a> traders that the company is scaling infrastructure to better support Solana during periods of high demand, addressing delays in activities like DEX trading and meme coin transactions. 
He stated that their goal is to provide tier 1 support for Solana, comparable to Bitcoin, Ethereum and Base, which also faced delays recently due to high activity.
Armstrong oncluded, "The surge in activity is great for the ecosystem but we need to do a better job serving our customers during periods of high demand."
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/01/43074520/solana-skyrockets-sees-15-surge-following-launch-of-trump-themed-meme-coin">Solana Skyrockets, Sees 15% Surge Following Launch Of Trump-Themed Meme Coin</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ETH

$SOL

$XRP

Solana Jumps 20% In 7 Days: Why Is SOL Going Up?

WIIM

MarineMax shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results.

GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) reported worse-than-expected fourth-quarter EPS and <a href="https://www.benzinga.com/news/earnings/25/01/43128325/ge-vernova-mixed-q4-revenue-misses-but-orders-surge-22-amid-strong-electrification-demand">revenue on Wednesday</a>.
The company reported revenue growth of 5% year-over-year to $10.559 billion and +9% organically, missing the consensus of $10.78 billion.
The company achieved orders totaling $13.2 billion, reflecting a 22% organic increase, ~1.3 times revenue, driven primarily by Power and Electrification equipment. Earnings per share for the quarter were $1.73, compared to $0.72 a year ago, missing the consensus of $2.55.
"GE Vernova built a strong foundation in 2024 with solid orders and revenue growth, as well as significant margin expansion and cash generation. We saw strength in Power and Electrification and improvement in Wind, while growing our equipment backlog at better margins," stated GE Vernova CEO Scott Strazik.
GE Vernova reaffirms its 2025 outlook with $36 billion – $37 billion in revenue versus a consensus of $36.88 billion, a high single-digit adjusted EBITDA margin, and $2 billion – $2.5 billion in free cash flow.
GE Vernova shares gained 2.7% to close at $427.10 on Wednesday.
These analysts made changes to their price targets on GE Vernova following earnings announcement.
<ul>
<li>JP Morgan analyst Mark Strouse maintained GE Vernova with an Overweight and raised the price target from $374 to $436.</li>
<li>Barclays analyst Julian Mitchell maintained the stock with an Overweight and raised the price target from $420 to $487.</li>
</ul>
Considering buying GEV stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="489" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23081255/image-174-1024x489.png" alt="" class="wp-image-746761" style="width:565px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23081255/image-174-1024x489.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23081255/image-174-300x143.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23081255/image-174-768x367.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23081255/image-174.png 1111w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43126364/jim-cramer-this-tech-stock-is-a-buy-amd-is-a-great-company">Jim Cramer: AMD Is A &#8216;Great&#8217; Company, Hold Onto Dow Inc.</a></li>
</ul>

Price Target

Analyst Ratings

GE Vernova Analysts Boost Their Forecasts After Strong Q4 Results

GE Aerospace CFO Says In 2025, Do Think Spare Parts To Stay Strong

EVTL

Vertical Aerospace shares are trading lower after the company announced a $90 million public offering.

Biotech

General

SELLAS Life Sciences Announces Interim Analysis For Phase 3 REGAL Trial Of GPS In Acute Myeloid Leukemia Showing; Says Independent Data Monitoring Committee Recommended Trial Continue Without Modifications

COEP

Coeptis Therapeutics Holdings Expands Its Technological Initiatives To Include Cutting-Edge Artificial Intelligence And Innovative Blockchain Solutions

Small Cap Consumer Research analyst Eric Beder reiterates Vince Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNCE#NYSE">VNCE</a>) with a Buy and maintains $6 price target.

Reiteration

VNCE

Small Cap Consumer Research Reiterates Buy on Vince Holding, Maintains $6 Price Target

Data corroborate previously reported preclinical data demonstrating certepetide's ability to enhance the effectiveness of immunotherapy
Preliminary results to be presented at the 2025 ASCO Gastrointestinal Cancers Symposium
BASKING RIDGE, N.J. and SUBIACO, Australia, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSTA#NASDAQ">LSTA</a>) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, and WARPNINE Incorporated ("WARPNINE"), Western Australia's first not-for-profit clinical research organization for pancreatic, gastro-intestinal and rare cancers, today announced encouraging preliminary results from the Phase 1b/2a iLSTA trial (<a href="https://www.globenewswire.com/Tracker?data=viG6Z8rb5yakmCziK5MC4KHIHD449o_0_iwBwzOnKLuIVX9ogOPIlIPp1gF8kKV4bkOsW4cHmYy5OZllI3q1fdfHwQ_EiqAKt0OJn1dwseNnLMKSutHtNTo4FzoF1DPTxQwyJFbH0lXRFKDo7QySmQ==">ACTRN12623000223639</a>) evaluating certepetide (formerly LSTA1), Lisata's proprietary investigational iRGD cyclic peptide product candidate, in combination with standard-of-care (SoC) chemotherapy and immunotherapy as a first-line treatment in locally advanced non-resectable pancreatic ductal adenocarcinoma (PDAC). The preliminary data will be presented in a poster session, entitled, "Immunotherapy combined with a novel iRGD peptide plus nab-paclitaxel and gemcitabine for locally advanced pancreatic ductal adenocarcinoma: A prospective study," at the 2025 American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium on Friday, January 24, 2025 at 11:30 a.m. - 1:00 p.m. (PST) in San Franscisco, California. For a detailed summary of the poster presentation, please see the abstract available on the ASCO GI website: <a href="https://www.globenewswire.com/Tracker?data=xhbTLxEjS_qv4xxw0rdbf9Rt0I_ukgclLSLtzTm27CY4aH8IsYbd4usSpVvBiLpC4lPd65aFQ8ovirYYzJtCon_gypsrzb3eZ8Am3EwukOPCVshYZxApc7bUzgoQWUApN9BvOUHo20-Tx0AxvGFbFPmy04pHaRoIuiyMBuEeQkZuPCIJxEmyVsPtYCxVjX4u">https://meetings.asco.org/abstracts-presentations/241611</a>
The Phase 1b/2a randomized, single-blind, single-center, safety and pharmacodynamic iLSTA trial, being conducted at St John of God Subiaco Hospital in Western Australia, a leading center for clinical research and innovation, is evaluating certepetide in combination with SoC chemotherapy (nab-paclitaxel and gemcitabine) plus SoC immunotherapy (durvalumab) versus SoC alone in patients with locally advanced non-resectable PDAC. This collaboration highlights the strength of combining global expertise with local excellence to address the urgent needs of patients with pancreatic cancer. Participants in the iLSTA trial were divided into three treatment cohorts (1:1:4 ratio): Cohort 1 (n=5) received SoC chemotherapy in combination with placebo durvalumab and placebo certepetide. Cohort 2 (n=5) received SoC chemotherapy plus certepetide and placebo durvalumab. Cohort 3 (n=20) received SoC chemotherapy plus durvalumab and certepetide. The preliminary results, representing an interim analysis of the first 17 of 30 targeted patients of the iLSTA trial are as follows:
Five of 16 patients evaluable by RECIST criteria experienced a partial response after 2 cycles of treatment (4 patients were in cohort 3), with the remaining 11 patients presenting with stable disease. After 4 cycles of treatment, 9 of 16 patients demonstrated partial response (8 patients were in cohort 3). Of the remaining 7 patients, 6 demonstrated stable disease, and 1 patient (cohort 2) exhibited a complete response. Fourteen of 17 patients who completed 4 treatment cycles showed a decrease in CA19-9 levels. Six patients demonstrated &gt;90% reduction in CA19-9 (5 of whom in cohort 3), with the remaining 8 patients showing a &gt;50% reduction in CA19-9 levels (6 of whom in cohort 3). Five patients had their repeat biopsies analyzed for tumor infiltrating lymphocytes (4 of whom from cohort 3), with all patients showing significant immune cell infiltration (15% to 50% stroma infiltration). These results demonstrate the potential value of adding certepetide to the SoC regimen consisting of gemcitabine, nab-paclitaxel, and durvalumab in this patient population.

LSTA

Lisata And WARPNINE Announces Interim Phase 1b/2a Results For Certepetide In Pancreatic Cancer; 56% Show Partial Response After 4 Cycles, With Up To 90% Reduction In CA19-9 Levels; Results To Be Presented At 2025 ASCO GI Symposium

Barclays analyst Jared Shaw maintains Wintrust Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTFC#NASDAQ">WTFC</a>) with a Overweight and raises the price target from $151 to $155.

WTFC

Barclays Maintains Overweight on Wintrust Finl, Raises Price Target to $155

Carter Bankshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARE#NASDAQ">CARE</a>) reported quarterly earnings of $0.37 per share which beat the analyst consensus estimate of $0.24 by 54.17 percent. This is a 1950 percent increase over losses of $(0.02) per share from the same period last year.

CARE

Carter Bankshares Q4 Adj $0.37 Beats $0.24 Estimate

BANC

Bank of California shares are trading higher after the company reported better-than-expected Q4 EPS results.

Press Releases

Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer's Disease at the Alzheimer's Association International Conference, Philadelphia, July 31, 2024

Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer's Disease

Health Care

Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer's Disease and Plans to Pursue a Development Partnership

Financing

Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds

Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference on October 31, 2024

Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference in Madrid, Spain

Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting

Vaccinex Provides Update on ActivMAb® Platform:  Multiple Project Deals and Presentation at SITC

Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Vaccinex Announces Receipt of Delisting Notification from Nasdaq

Comments

Vaccinex

Vaccinex (VCNX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga